Page last updated: 2024-11-13

selurampanel

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

selurampanel: anticonvulsant that antagonizes both AMPA and kainate receptors [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID45381907
CHEMBL ID3545042
SCHEMBL ID1660562
MeSH IDM000597226

Synonyms (23)

Synonym
n-[7-isopropyl-6-(2-methyl-2h-pyrazol-3-yl)-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl]-methanesulfonamide
MCECSFFXUPEPDB-UHFFFAOYSA-N
7wg1mr7dar ,
bgg 492a
selurampanel [inn]
selurampanel
bgg 492
unii-7wg1mr7dar
912574-69-7
bgg492
selurampanel [who-dd]
bgg-492
n-(6-(1-methyl-1h-pyrazol-5-yl)-7-(propan-2-yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2h)-yl)methanesulfonamide
SCHEMBL1660562
CHEMBL3545042
DTXSID00238467
DB12367
AKOS032946688
n-[6-(2-methylpyrazol-3-yl)-2,4-dioxo-7-propan-2-yl-1h-quinazolin-3-yl]methanesulfonamide
Q21098868
SB17404
HY-105860
CS-0026799

Research Excerpts

Overview

Selurampanel (BGG492) is an experimental competitive AMPA antagonist currently in clinical trials.

ExcerptReferenceRelevance
"Selurampanel (BGG492) is an experimental competitive AMPA antagonist currently in clinical trials."( BGG492 (selurampanel), an AMPA/kainate receptor antagonist drug for epilepsy.
Faught, E, 2014
)
1.56

Toxicity

ExcerptReferenceRelevance
" Adverse events were reported by 80%, 56%, and 60% of BGG492, sumatriptan, and placebo subjects, respectively."( Randomized, multicenter trial to assess the efficacy, safety and tolerability of a single dose of a novel AMPA receptor antagonist BGG492 for the treatment of acute migraine attacks.
Brand, R; Campos, V; Diener, HC; Evers, S; Göbel, H; Gomez-Mancilla, B; Hariry, S; Johns, D; Jürgens, TP; Kalkman, HO; Pezous, N; Sommer, C; Sommer, M; Straube, A, 2014
)
0.4
" Safety was assessed by recording all adverse events (AEs)."( Efficacy and safety of single- and repeated-selurampanel dosing for 2 weeks in patients with chronic subjective tinnitus: Results of a randomized, double-blind, placebo-controlled, cross-over, proof-of-concept phase IIa study.
Abd-Elaziz, K; Derne, C; Johns, D; Kucher, K; Langguth, B; Pfister, CU; Sverdlov, O; Wagner, F, 2021
)
0.88

Bioavailability

ExcerptReferenceRelevance
" Guided by ionic liquid structure, in vivo profiles ranged from rapid bioavailability and high maximal plasma concentrations to sustained patterns."( Mapping the pharmaceutical design space by amorphous ionic liquid strategies.
Balk, A; Bruhn, H; Dekant, W; Galli, B; Holzgrabe, U; Lühmann, T; Meinel, L; Merget, B; Picard, F; Raccuglia, M; Saedtler, M; Sotriffer, C; Stopper, H; Walid, E; Widmer, T; Wiest, J, 2017
)
0.46

Dosage Studied

ExcerptRelevanceReference
"To evaluate dose-response relationship of BGG492 as add-on therapy to 1-3 antiepileptic drugs in patients with partial-onset seizures and to investigate safety and tolerability of BGG492."( BGG492 as an adjunctive treatment in patients with partial-onset seizures: A 12-week, randomized, double-blind, placebo-controlled, phase II dose-titration study with an open-label extension.
Brandt, C; Elger, CE; Han, J; Hong, SB; Mancione, L; Strohmaier, C, 2017
)
0.46
" In the core study, no statistically significant dose-response trend among the BGG492 treatment groups (100 and 150 mg) was observed at the 4-week double-blind maintenance period (weeks 7-10); however, there was higher percent reduction in total partial seizure frequency in the BGG492 150 mg over placebo groups (37."( BGG492 as an adjunctive treatment in patients with partial-onset seizures: A 12-week, randomized, double-blind, placebo-controlled, phase II dose-titration study with an open-label extension.
Brandt, C; Elger, CE; Han, J; Hong, SB; Mancione, L; Strohmaier, C, 2017
)
0.46
"There was no significant dose-response trend in the BGG492 treatment groups (100 and 150 mg); however, higher percent reduction over placebo was observed in the BGG492 150 mg group."( BGG492 as an adjunctive treatment in patients with partial-onset seizures: A 12-week, randomized, double-blind, placebo-controlled, phase II dose-titration study with an open-label extension.
Brandt, C; Elger, CE; Han, J; Hong, SB; Mancione, L; Strohmaier, C, 2017
)
0.46
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's8 (88.89)24.3611
2020's1 (11.11)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 21.21

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index21.21 (24.57)
Research Supply Index2.64 (2.92)
Research Growth Index4.55 (4.65)
Search Engine Demand Index18.60 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (21.21)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials4 (44.44%)5.53%
Reviews3 (33.33%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other2 (22.22%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]